$MBRXSep 14, 2026, 8:35 AM ETAI processed
MBRX to present Annamycin tissue-distribution, topo II mechanism and CD8+ T-cell data at AACR & EU meetings
AI Summary
Moleculin (MBRX) will present new Annamycin (naxtarubicin) data at three September scientific meetings, including the AACR pancreatic cancer conference; presentations cover the drug's organotropism (tissue concentration), its topoisomerase II–targeting mechanism, and evidence that antitumor activity is partially mediated by CD8+ T cells in preclinical models. The AACR abstract is under embargo until Sept 25, and the company says these mechanistic/preclinical data complement — but do not replace — its ongoing MIRACLE Phase 2/3 program in relapsed/refractory AML, which remains the lead clinical focus.
Positives
- New Annamycin data will be presented at AACR pancreatic cancer conference plus two European scientific meetings
- Presentations report organotropism — Annamycin concentrates in specific tissues — which may inform target indications
- Preclinical evidence suggests Annamycin kills cancer via topoisomerase II inhibition and has partial CD8+ T-cell–mediated antitumor activity
Negatives
- Key AACR abstract is under embargo and the findings are not yet publicly available
- Data described are preclinical/mechanistic and early, not proof of clinical benefit
- Company notes prior interim efficacy trends were from a small sample (n=45) and were not statistically significant